Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study

Hongnan Mo, Binghe Xu, Jiachen Xu et al.|British Journal of Cancer|2018

Cited by 156